The phase II data are promising for patients who are managed with watchful waiting before being offered an intervention.

Ataciguat, a new drug being studied for aortic valve stenosis, shows promise in slowing disease progression and reducing the ...

The nitric oxide-independent soluble guanylate cyclase activator ataciguat continued to show promise for slowing the ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally. Researchers are exploring the use of a new drug called ataciguat to manage ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.

A new study has revealed the existence of bifunctional diterpene cyclases/synthases (DCSs) in bacteria, offering compelling ...

Those with MCI are at a heightened risk for developing dementia or Alzheimer’s disease, with approximately 10% progressing to ...

The PAH treatment market is expected to grow from USD 5,811.5 million in 2023 to USD 7,224.4 million by 2033, at a CAGR of ...

Roivant's $7.1B Telavant sale to Roche demonstrated potential, but the company's stock has underperformed, trading flat while the S&P 500 gained 19% since April. Brepocitinib shows promise for NIU ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 78 tables and 119 figures, this 215-page report ?Global Biopharmaceuticals Market 2023-2033 by Product Type, Testing ...

State Key Laboratory of Microbial Metabolism and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China Zhangjiang Institute for Advanced Study, Shanghai Jiao ...

National and Local United Engineering Research Center of Industrial Microbiology and Fermentation Technology, Engineering Research Center of Industrial Microbiology of Ministry of Education, College ...